Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Birelentinib - Dizal Pharmaceutical

Next Previous
Drug Profile

Birelentinib - Dizal Pharmaceutical

Alternative Names: BTK-IN-30; DZD-8586; GTPL13735

Latest Information Update: 12 Dec 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Dizal Pharmaceutical
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Agammaglobulinaemia tyrosine kinase inhibitors; Lyn protein-tyrosine kinase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma
  • Phase I/II Non-Hodgkin's lymphoma

Most Recent Events

  • 09 Dec 2024 Updated safety and efficacy data from a phase I/II trial Non-Hodgkin's lymphoma released by Dizal Pharmaceutical
  • 29 Apr 2024 Phase-II clinical trials in Chronic lymphocytic leukaemia (Second-line therapy or greater) in China (PO) (NCT06539182)
  • 13 Mar 2024 Phase-II clinical trials in Diffuse large B cell lymphoma (Second-line therapy or greater, Recurrent) in China (PO) (NCT06539195)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top